Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Clinical trials of onercept for psoriasis, Canvaxin for melanoma discontinued
May 5th, 2005
Serono (SRA) announced the discontinuation of 2 phase 3 clinical trial programs: onercept (recombinant tumor necrosis factor binding protein) in moderate-to-severe psoriasis and Canvaxin in stage 4 melanoma, licensed from CancerVax. The decision to discontinue these clinical trials is based on the recommendations of 2 separate independent data and safety monitoring boards (DSMBs). In 2004, Serono initiated 3 phase 3 clinical trials in moderate-to-severe psoriasis. Investigators have recently reported 2 patients diagnosed with sepsis, one of whom subsequently died. Sepsis is a recognized potential risk for patients treated with anti-tumor necrosis...
Source: Women's Health Weekly (2005-05-05)
|
